You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Phase Ib trial

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CCHF Trial (Favipiravir, Ribavirin)

Not yet recruiting
  • CCHF
  • (no location specified)
Jul 7, 2023

Advanced Solid Tumor Trial in Shanghai (JS015, Toripalimab, Paclitaxel)

Not yet recruiting
  • Advanced Solid Tumor
  • JS015
  • +10 more
  • Shanghai, Shanghai, China
    Shanghai East Hospital
Nov 17, 2023

Advanced Solid Tumors Trial (AK127 in combination with AK112)

Not yet recruiting
  • Advanced Solid Tumors
  • AK127 in combination with AK112
  • (no location specified)
Jul 11, 2023

Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

Recruiting
  • Acute Gout
  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
  • +6 more
  • Wuhan, Hubei, China
  • +2 more
Oct 17, 2022

Sarcoma Trial in Guangzhou (Fluzoparib+ Dalpiciclib)

Recruiting
  • Sarcoma
  • Fluzoparib+ Dalpiciclib
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University (CCSYSU)
Jul 11, 2023

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Advanced Solid Tumors Trial (SHR-A2009 for injection ; Almonertinib Mesilate Tablets, SHR-A2009 for injection;Adebrelimab

Not yet recruiting
  • Advanced Solid Tumors
  • SHR-A2009 for injection ； Almonertinib Mesilate Tablets
  • SHR-A2009 for injection；Adebrelimab Injection
  • (no location specified)
Oct 17, 2023

Refractory Solid Tumors Trial in Houston (Eribulin, Irinotecan, Temozolomide)

Recruiting
  • Refractory Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2023

Heart Failure With Reduced Ejection Fraction Trial (AC01)

Not yet recruiting
  • Heart Failure With Reduced Ejection Fraction
  • (no location specified)
Jan 31, 2023

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

Bone Cancer Trial in Villejuif (regorafenib tablet)

Recruiting
  • Bone Cancer
  • regorafenib tablet
  • Villejuif, Ile De France, France
    Gustave Roussy
Apr 13, 2023

Advanced Solid Tumors Trial (PE0116,PE0105)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Sep 6, 2023

NASH, NAFLD Trial in Hangzhou (GH509, Placebo)

Recruiting
  • NASH
  • NAFLD
  • Hangzhou, Zhejiang, China
    The Affiliated Hospital of Hangzhou Normal University
Mar 26, 2023

Advanced Solid Tumor Trial (Adebrelimab, SHR-1802, Carboplatin/Cisplatin)

Not yet recruiting
  • Advanced Solid Tumor
  • Adebrelimab
  • +3 more
  • (no location specified)
Mar 20, 2023

Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction (GEJ) Cancer
  • T-Dxd(Trastuzmab deruxtecan), Ramucirumab
  • (no location specified)
Jun 7, 2023

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Addiction, Opioid Use, Substance Use Disorders Trial (Placebo, Auvelity)

Not yet recruiting
  • Addiction
  • +3 more
  • (no location specified)
Aug 3, 2023

Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    M.D. Anderson Cancer Center
Apr 17, 2023

Melanoma Trial in Beijing (IBI363)

Not yet recruiting
  • Melanoma
  • IBI363
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 7, 2023

Rheumatoid Arthritis Trial (VC005 tablets, VC005 Tablets Placebo)

Not yet recruiting
  • Rheumatoid Arthritis
  • VC005 tablets
  • VC005 Tablets Placebo
  • (no location specified)
May 24, 2023

Advanced Liver Cancer Trial in Chengdu (QL1706, QL1604, Bevacizumab)

Recruiting
  • Advanced Liver Cancer
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Nov 1, 2022

Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • +3 more
  • Lenvatinib/Pembrolizumab plus SBRT combinations
  • Taipei City, Taiawn, Taiwan
    National Taiwan University Hospital
Jan 30, 2023

Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with

Recruiting
  • Inhibition of Autophagy Synergizes Anti-tumor Effect
  • 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
  • RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023

Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)

Not yet recruiting
  • Esophagogastric Adenocarcinoma
  • Sacituzumab govitecan
  • (no location specified)
Nov 9, 2023

Non-hodgkin's Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jan 12, 2023